stoxline Quote Chart Rank Option Currency Glossary
  
ARCA biopharma, Inc. (ABIO)
3.5  0.24 (7.36%)    06-21 16:00
Open: 3.29
High: 3.55
Volume: 108,088
  
Pre. Close: 3.26
Low: 3.1401
Market Cap: 51(M)
Technical analysis
2024-06-21 4:50:21 PM
Short term     
Mid term     
Targets 6-month :  4.53 1-year :  5.24
Resists First :  3.88 Second :  4.48
Pivot price 3.37
Supports First :  2.9 Second :  2.41
MAs MA(5) :  3.32 MA(20) :  3.38
MA(100) :  2.61 MA(250) :  2.19
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  39.8 D(3) :  35
RSI RSI(14): 55.7
52-week High :  4.48 Low :  1.55
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABIO ] has closed below upper band by 29.9%. Bollinger Bands are 6.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.55 - 3.58 3.58 - 3.6
Low: 3.1 - 3.12 3.12 - 3.14
Close: 3.47 - 3.51 3.51 - 3.54
Company Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Headline News

Sun, 16 Jun 2024
Cable Car Capital LLC Takes $6.80 Million Position in ARCA biopharma, Inc. (NASDAQ:ABIO) - Defense World

Wed, 22 May 2024
Kuehn Law Encourages ABIO, SQSP, SSB, and HMNF Investors to Contact Law Firm - Morningstar

Thu, 25 Apr 2024
ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 - InvestorPlace

Wed, 03 Apr 2024
Arca Biopharma's Strategic Merger with Oruka Therapeutics - TipRanks.com - TipRanks

Wed, 03 Apr 2024
ARCA biopharma and Oruka Therapeutics announce merger By Investing.com - Investing.com

Wed, 03 Apr 2024
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 15 (M)
Shares Float 5 (M)
Held by Insiders 1.2 (%)
Held by Institutions 75 (%)
Shares Short 4,100 (K)
Shares Short P.Month 5,660 (K)
Stock Financials
EPS -0.42
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.42
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -12.7 %
Return on Equity (ttm) -15.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.55
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -8.34
PEG Ratio 0
Price to Book value 1.44
Price to Sales 0
Price to Cash Flow -10.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android